Last Updated: November 16, 2026

ATTRUBY Drug Patent Profile

« Back to Dashboard


When do Attruby patents expire, and what generic alternatives are available?

Attruby is a drug marketed by Bridgebio Pharma and is included in one NDA. There are thirteen patents protecting this drug.

The generic ingredient in ATTRUBY is acoramidis hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the acoramidis hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Attruby

Attruby will be eligible for patent challenges on November 22, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 16, 2039. This may change due to patent challenges or generic licensing.

There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ATTRUBY?
  • What are the global sales for ATTRUBY?
  • What is Average Wholesale Price for ATTRUBY?
Summary for ATTRUBY
US Patents:13
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for ATTRUBY
What excipients (inactive ingredients) are in ATTRUBY?ATTRUBY excipients list
DailyMed Link:ATTRUBY at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ATTRUBY
Generic Entry Date for ATTRUBY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ATTRUBY

US Patents and Regulatory Information for ATTRUBY

ATTRUBY is protected by thirteen US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ATTRUBY is ⤷  Start Trial.

This potential generic entry date is based on patent 11,260,047.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes 9,169,214 ⤷  Start Trial Y ⤷  Start Trial
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes 12,005,043 ⤷  Start Trial Y ⤷  Start Trial
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes 10,842,777 ⤷  Start Trial ⤷  Start Trial
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes 10,513,497 ⤷  Start Trial Y ⤷  Start Trial
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes 10,398,681 ⤷  Start Trial Y ⤷  Start Trial
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ATTRUBY

When does loss-of-exclusivity occur for ATTRUBY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 19321583
Estimated Expiration: ⤷  Start Trial

Patent: 25226697
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2020026493
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 04695
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 21000289
Estimated Expiration: ⤷  Start Trial

China

Patent: 2804998
Estimated Expiration: ⤷  Start Trial

Patent: 2056844
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0251603
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 36920
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 2190561
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 36920
Estimated Expiration: ⤷  Start Trial

Patent: 47068
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 36920
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 0906
Estimated Expiration: ⤷  Start Trial

Patent: 5404
Patent: פורמולציות של תבליות המכילות 3-(3-(5,3-דימתיל-1h-פירזול-4-יל)פרופוקסי)-4-פלואורו-חומצה בנזואית (Tablet formulations of 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 69293
Estimated Expiration: ⤷  Start Trial

Patent: 60163
Estimated Expiration: ⤷  Start Trial

Patent: 21534189
Patent: AG10の製剤
Estimated Expiration: ⤷  Start Trial

Patent: 24083460
Patent: AG10の製剤 (FORMULATIONS OF AG10)
Estimated Expiration: ⤷  Start Trial

Patent: 26110857
Patent: AG10の製剤
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 36920
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 21001761
Patent: FORMULACIONES DE AG10. (FORMULATIONS OF AG10.)
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 238
Patent: FORMULES D'AG10
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 4039
Patent: Formulations of ag10
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 36920
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 36920
Estimated Expiration: ⤷  Start Trial

San Marino

Patent: 02500463
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 572
Patent: FORMULACIJE AG10 (FORMULATIONS OF AG10)
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 202101393P
Patent: FORMULATIONS OF AG10
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 36920
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 210046708
Patent: AG10의 제형
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 55121
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 2021583
Patent: Formulations of AG10
Estimated Expiration: ⤷  Start Trial

Patent: 34708
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 8256
Patent: ПРЕПАРАТИ AG10 (FORMULATIONS OF AG10)
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ATTRUBY around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1120543 ⤷  Start Trial
Cyprus 2025010 ⤷  Start Trial
Denmark 2934514 ⤷  Start Trial
European Patent Office 2934514 STABILISANTS DE TRANSTHYRÉTINE ET LEUR UTILISATION POUR INHIBER L'AMYLOSE DE LA TRANSTHYRÉTINE ET LES INTERACTIONS PROTÉINE-PROTÉINE (TRANSTHYRETIN STABILIZERS AND THEIR USE FOR INHIBITING TRANSTHYRETIN AMYLOIDOSIS AND PROTEIN-PROTEIN INTERACTIONS) ⤷  Start Trial
Spain 2683994 ⤷  Start Trial
Finland C20250016 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ATTRUBY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2934514 301323 Netherlands ⤷  Start Trial PRODUCT NAME: ACORAMIDIS EN/OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER ACORAMIDISHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/24/1906 20250211
2934514 C20250016 Finland ⤷  Start Trial
2934514 CA 2025 00013 Denmark ⤷  Start Trial PRODUCT NAME: ACORAMIDIS, AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY ACORAMIDIS HYDROCHLORIDE; REG. NO/DATE: EU/1/24/1906 20250211
2934514 PA2025512 Lithuania ⤷  Start Trial PRODUCT NAME: AKORAMIDIS IR/ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPACAKORAMIDZIO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/24/1906 20250210
2934514 CR 2025 00013 Denmark ⤷  Start Trial PRODUCT NAME: ACORAMIDIS, AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY ACORAMIDIS HYDROCHLORIDE; REG. NO/DATE: EU/1/24/1906 20250211
2934514 LUC50002 Luxembourg ⤷  Start Trial PRODUCT NAME: ACORAMIDIS, ET/OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE CHLORHYDRATE D'ACORAMIDIS; AUTHORISATION NUMBER AND DATE: EU/1/24/1906 20250210
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

ATTRUBY Market Dynamics and Financial Trajectory: Acoramidis Commercial Outlook

Last updated: October 28, 2026

ATTRUBY, the brand name for acoramidis, entered the U.S. market in early 2025 as the second approved disease-modifying therapy for transthyretin amyloid cardiomyopathy, or ATTR-CM. Its commercial opportunity is large because ATTR-CM is underdiagnosed and treatment is chronic, but market share will depend on payer access, cardiology adoption, diagnostic expansion and competition with Pfizer's VYNDAMAX.

BridgeBio Pharma and its subsidiary Eidos Therapeutics developed acoramidis. The FDA approved ATTRUBY on November 22, 2024, for adults with wild-type or hereditary ATTR-CM to reduce cardiovascular death and cardiovascular hospitalization.[1] The product generated approximately $30 million in net product revenue in its first reported commercial quarter, according to BridgeBio's first-quarter 2025 reporting.[2]

What is ATTRUBY and which patients does it treat?

ATTRUBY is oral acoramidis hydrochloride, a transthyretin stabilizer dosed at 800 mg twice daily. It is indicated for adults with wild-type or hereditary ATTR-CM.[1]

ATTR-CM occurs when transthyretin protein misfolds and deposits in cardiac tissue. The disease has two principal forms:

ATTR-CM subtype Underlying cause Commercial relevance
Wild-type ATTR-CM Age-associated transthyretin misfolding Largest addressable patient segment
Hereditary ATTR-CM TTR gene mutation Smaller population with greater genetic and geographic concentration

The FDA approval was supported by the Phase 3 ATTRibute-CM study, which enrolled 632 patients with ATTR-CM. The trial evaluated a hierarchical composite of all-cause mortality, cardiovascular hospitalization, change in N-terminal pro-B-type natriuretic peptide and six-minute walk distance.[1]

ATTRUBY competes directly with tafamidis, marketed by Pfizer as VYNDAMAX and VYNDAQEL. Both products stabilize transthyretin, but acoramidis has a differentiated clinical positioning based on its mechanism and the ATTRibute-CM results. Direct market conversion will depend on physician interpretation of comparative evidence because ATTRUBY and tafamidis have not been tested against each other in a head-to-head outcomes trial.

How large is the ATTR-CM market?

The commercial market is expanding through diagnosis rather than only through treatment substitution. ATTR-CM historically was identified late or misclassified as hypertensive heart disease, hypertrophic cardiomyopathy or heart failure with preserved ejection fraction.

Market expansion depends on four factors:

  1. Greater use of technetium-based bone scintigraphy and genetic testing.
  2. Recognition of ATTR-CM in older patients with heart failure, increased ventricular wall thickness or carpal tunnel syndrome.
  3. Treatment of patients earlier in the disease course.
  4. Broader cardiology prescribing beyond specialist amyloidosis centers.

The addressable population is difficult to quantify because prevalence estimates vary substantially by diagnostic method and geography. Wild-type ATTR-CM is concentrated in older men, while hereditary disease prevalence is materially higher in certain regions and ethnic groups.

Acoramidis has a favorable market structure because treatment is chronic and disease-modifying therapy is generally continued for as long as patients remain clinically eligible. The principal constraint is diagnosis. A drug cannot generate revenue from patients who have not been identified as having ATTR-CM.

What is ATTRUBY's financial trajectory?

ATTRUBY had no meaningful commercial revenue before U.S. launch. The FDA approval in November 2024 created the regulatory basis for commercial sales, and the product began generating revenue in the first quarter of 2025.

Financial milestone Timing Commercial implication
FDA approval November 22, 2024 Regulatory entry into the U.S. ATTR-CM market
U.S. launch Early 2025 Start of commercial revenue generation
First reported commercial quarter Q1 2025 Approximately $30 million in net product revenue
Revenue trajectory 2025 onward Dependent on payer access, diagnosis and new-patient starts

BridgeBio's first-quarter 2025 results indicated that ATTRUBY had begun contributing material product revenue shortly after launch.[2] The initial sales figure should be interpreted as a launch-period indicator, not a steady-state run rate. Early revenue typically includes initial prescriptions from high-volume specialty centers and does not yet reflect the full impact of payer contracting, community cardiology adoption or diagnostic expansion.

The principal revenue drivers are:

  • New patient identification.
  • Conversion of patients treated with tafamidis.
  • Treatment of patients previously managed without disease-modifying therapy.
  • Refill persistence.
  • Access through Medicare and commercial insurance.
  • Expansion of hereditary ATTR-CM testing and treatment.

The largest financial risk is a slower-than-expected ramp in diagnosed patients. ATTRUBY's commercial performance is less dependent on one-time demand than on the rate at which the overall ATTR-CM treatment population expands.

How does ATTRUBY compare with VYNDAMAX?

VYNDAMAX is the incumbent U.S. therapy and has substantial commercial advantages, including earlier approval, established guideline recognition, physician familiarity and a large treated-patient base. ATTRUBY enters with clinical differentiation and a second-source dynamic in a market that has been dominated by one branded product.

Factor ATTRUBY VYNDAMAX
Active ingredient Acoramidis Tafamidis
Developer Eidos Therapeutics/BridgeBio Pfizer
FDA ATTR-CM approval November 2024 May 2019
Mechanism TTR stabilization TTR stabilization
Dosing 800 mg twice daily 80 mg once daily
Key trial ATTRibute-CM ATTR-ACT
Market position New entrant Established leader
Main commercial challenge Building diagnosis and access Defending share and pricing

ATTRUBY may gain share from physicians who view acoramidis as a strong stabilizer or who prefer a second treatment option. Pfizer's installed base, payer relationships and years of clinical use create a significant switching barrier.

The most important competitive question is whether ATTRUBY expands the category or primarily captures patients who otherwise would have received tafamidis. Category expansion would support rapid growth for both products. Heavy switching would increase payer pressure and could reduce net pricing across the class.

What FDA regulatory status and exclusivity apply to ATTRUBY?

ATTRUBY has full FDA approval under the New Drug Application pathway. The approval covers treatment of adult patients with wild-type or hereditary ATTR-CM.[1]

The approval does not make ATTRUBY a biologic, so biosimilar competition is not the relevant future threat. The principal long-term threat is small-molecule generic competition after applicable regulatory exclusivity and patent protection expire.

The FDA's approval grants regulatory exclusivity only if the statutory criteria are met and the relevant exclusivity is listed in FDA records. ATTRUBY's principal commercial protection is expected to come from patents covering acoramidis, pharmaceutical compositions, methods of treatment and potentially manufacturing processes. Exact Orange Book listings and expiration dates should be taken from the current FDA Orange Book because listing status can change through patent certifications, delistings and regulatory updates.

What patents protect ATTRUBY and when could generic entry occur?

The ATTRUBY patent estate is expected to include several protection categories:

Composition-of-matter patents

These cover acoramidis or closely defined chemical compounds. Composition claims generally provide the strongest protection because a generic product cannot lawfully market the same active ingredient while valid claims remain enforceable.

Formulation and pharmaceutical-composition patents

These may cover the active ingredient in specific oral dosage forms, salt forms, excipient systems, particle characteristics or release profiles. Their value depends on claim scope and whether a generic can design around them.

Method-of-use patents

These may cover treatment of ATTR-CM, reduction of cardiovascular mortality or hospitalization, dosing regimens and treatment of genetically defined disease populations. Method-of-use patents can create narrower barriers than composition patents because generic applicants may attempt a section viii label carve-out.

Manufacturing patents

Process patents may cover preparation, purification, crystallization or salt formation. They can raise development and supply-chain costs but are generally less decisive than a valid composition patent unless the process is difficult to design around.

Public regulatory and company disclosures establish ATTRUBY's approval and commercial ownership, but they do not provide a reliable basis here for assigning a single generic-entry date. Generic entry would depend on the earliest enforceable patent expiry, FDA exclusivity, any pediatric extension, Paragraph IV litigation and settlement terms.

Are there Paragraph IV challenges or ATTRUBY patent lawsuits?

No material public Paragraph IV challenge, final court judgment or commercial settlement affecting ATTRUBY's U.S. launch had been disclosed in the sources used for this analysis through the early commercial period.

A future ANDA challenger would need to address listed patents through one or more of the following positions:

  • Paragraph IV certification that a listed patent is invalid, unenforceable or not infringed.
  • Paragraph III certification accepting delayed approval until patent expiry.
  • Section viii statement carving out patented methods from the proposed label.
  • Non-infringement arguments directed to formulation or process claims.

A Paragraph IV filing could trigger a 30-month stay of FDA approval under the Hatch-Waxman framework if the patent holder files an infringement action within the statutory period.[3] The practical impact would depend on which patents are challenged and whether composition claims survive early litigation.

How strong is the ATTRUBY patent and commercial estate?

ATTRUBY's commercial estate is strong in market terms but remains untested in litigation. Its main advantages are:

  • A novel branded entrant in a concentrated disease category.
  • Chronic use and potentially high treatment persistence.
  • A full FDA approval supported by an outcomes trial.
  • A large incumbent market available for conversion.
  • No immediate biosimilar pathway.

The main weaknesses are:

  • A small-molecule product is eventually exposed to ANDA competition.
  • Method-of-use patents may be vulnerable to label carve-outs.
  • Formulation patents may be designed around.
  • A high treatment cost can increase payer management.
  • Comparative clinical uncertainty may limit switching from tafamidis.
  • The disease population remains underdiagnosed.

Patent strength should be assessed claim by claim. A broad, enforceable composition patent would materially improve the revenue duration. A portfolio consisting mainly of narrow formulation and method claims would provide less reliable protection.

What licensing and commercialization arrangements affect ATTRUBY?

BridgeBio and Eidos are the central commercial entities associated with acoramidis. ATTRUBY is not a product marketed by Pfizer, despite competing directly with Pfizer's VYNDAMAX.

The commercial model gives BridgeBio exposure to both product sales and the costs of building a specialty cardiovascular franchise. Key expense areas include sales personnel, market access, patient support, medical education and post-approval evidence generation.

The absence of a major global commercial partner may preserve economics for BridgeBio but increases execution risk outside the United States. International expansion requires country-specific approvals, reimbursement negotiations, pricing decisions and distribution infrastructure.

What generic launch scenarios exist for ATTRUBY?

Three launch scenarios are commercially relevant:

Scenario Timing Market effect
Early challenge with settlement Before core patent expiry Potential authorized or licensed generic entry
Litigation-driven delayed entry Near patent expiry Continued branded sales until court or settlement resolution
Full patent-term protection After core expiry Maximum revenue duration, followed by price erosion

Generic erosion would likely be rapid if multiple manufacturers enter simultaneously and the product has no meaningful formulation barrier. ATTRUBY could retain some value through physician preference, supply reliability or patient support, but small-molecule branded products generally face substantial price pressure after generic entry.

How does ATTRUBY's geographic opportunity compare with the U.S.?

The United States is the initial economic center because it has the largest diagnosed commercial market and the most developed reimbursement infrastructure for specialty cardiology products.

International value depends on:

  • Approval by the European Medicines Agency and other national regulators.
  • Recognition of ATTR-CM as a reimbursable indication.
  • Availability of diagnostic testing.
  • Hereditary ATTR prevalence.
  • National pricing controls.
  • Local patent enforceability.

Hereditary ATTR-CM could be commercially important in Brazil, Portugal, Japan and other regions with higher prevalence of specific TTR mutations. Wild-type ATTR-CM offers a broader but older patient population and may require more intensive diagnostic investment.

Key Takeaways

  • ATTRUBY is acoramidis, an oral TTR stabilizer approved by the FDA in November 2024 for adult wild-type and hereditary ATTR-CM.
  • BridgeBio reported approximately $30 million in first-quarter 2025 net product revenue, establishing an early commercial base.
  • VYNDAMAX remains the incumbent competitor, but ATTRUBY creates the first meaningful branded alternative in the U.S. ATTR-CM market.
  • Long-term growth depends more on diagnosis, payer access and treatment persistence than on regulatory approval alone.
  • The product is a small molecule, so future generic competition under the Hatch-Waxman framework is the main erosion risk.
  • Exact generic-entry timing depends on current Orange Book listings, patent validity, Paragraph IV litigation and any settlement agreements.
  • ATTRUBY does not face a biosimilar pathway because it is not a biologic.
  • The largest financial upside comes from market expansion and conversion of tafamidis-treated patients. The largest risks are slow diagnosis, payer restrictions and weak comparative differentiation.

FAQs

What is the annual price of ATTRUBY?

ATTRUBY is a high-cost chronic specialty medicine. The relevant commercial measure is net price after rebates and patient assistance, not only wholesale acquisition cost. BridgeBio's financial filings provide the most reliable basis for assessing realized product economics.

Is ATTRUBY better than VYNDAMAX?

No head-to-head outcomes trial establishes superiority. ATTRUBY and VYNDAMAX have different pivotal trials, so physicians and payers must compare cross-trial evidence cautiously.

Can ATTRUBY be used for ATTR polyneuropathy?

The FDA approval discussed here is for ATTR-CM. Use in ATTR polyneuropathy should not be assumed to have the same regulatory status.

Is acoramidis a gene-silencing therapy?

No. Acoramidis stabilizes transthyretin. It does not silence the TTR gene or reduce TTR production in the manner of RNA interference or antisense therapies.

What would most increase ATTRUBY sales?

Earlier diagnosis, broader reimbursement, strong refill persistence and evidence supporting use before advanced cardiac disease would have the greatest effect on revenue growth.

References

  1. U.S. Food and Drug Administration. (2024). ATTRUBY (acoramidis hydrochloride) prescribing information and approval announcement. FDA.

  2. BridgeBio Pharma, Inc. (2025). First-quarter 2025 financial results and business update. BridgeBio Pharma.

  3. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug application patent certifications. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.